Meeting
2018 ASCO Annual Meeting
Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.
Authors
Ajay Dhakal
Roswell Park Cancer Institute, Buffalo, NY
Ajay Dhakal , Roby Antony Thomas , Ellis Glenn Levine , Adam Brufsky , Matthew G Hanna , Austin Miller , Thaer Khoury , Kazuaki Takabe , Amy P. Early , Tracy O'Connor , Mateusz Opyrchal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1064)
DOI
10.1200/JCO.2018.36.15_suppl.1064
Abstract #
1064
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.
First Author: Xiaoliang Wang
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz